Why the study?
The study was conducted to identify key routinely used myopathologic biomarkers of facioscapulohumeral muscular dystrophy type 1 (FSHD1).
What are the key myopathologic biomarkers of facioscapulohumeral muscular dystrophy type 1 (FSHD1) in muscle biopsies compared to healthy controls?
What are the key myopathologic biomarkers of facioscapulohumeral muscular dystrophy type 1 (FSHD1) in muscle biopsies compared to healthy controls?
MHC I, MAC, and embryonic Myosin Heavy Chain/muscle regeneration are useful myopathologic readouts for characterizing FSHD1.
Routine myopathologic markers may support FSHD1 diagnosis; leaves open prospective validation before clinical adoption.
The aim of this study was to identify key routinely used myopathologic biomarkers of FSHD1. Needle muscle biopsies were taken in 34 affected muscles (m. quadriceps femoris (QF), n = 20, m. tibialis anterior (TA), n = 13, m. biceps brachii, n = 1) from 22 patients (age, 53.5 (10) years; M = 12, F = 10). Eleven patients had more than one biopsy (2xQF, n = 1; QF+TA, n = 9; 2xQF+TA, n = 1). Histochemistry, immunoperoxidase, and immunofluorescence stainings were performed and compared to age and muscle type matched muscle specimens of 11 healthy controls. Myopathologic features observed in our FSHD1 cohort were internalized nuclei, type 1 fibre hypertrophy and NADH central clearances/cores. We observed a prominent inflammatory response with MAC deposits, MHC I expression, and muscle regeneration that correlated with the inflammatory score. Our up-to-date characterization of FSHD1 points towards MHC I, MAC, and embryonic Myosin Heavy Chain/muscle regeneration as useful myopathologic readouts of FSHD1.
No takes yet. Share an insight, caveat, or question.
Hubregtse et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: